MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Xenon Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

32.65 3.98

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.29

Max

33.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

638K

-65M

Pardavimai

7.5M

7.5M

Pelno marža

-867.293

Darbuotojai

316

EBITDA

4.1M

-73M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+76.1% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-303M

2.4B

Ankstesnė atidarymo kaina

28.67

Ankstesnė uždarymo kaina

32.65

Naujienos nuotaikos

By Acuity

68%

32%

343 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-09 15:46; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250 Million Private Placement

2025-07-09 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 20:26; UTC

Uždarbis

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025-07-09 19:18; UTC

Rinkos pokalbiai

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025-07-09 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025-07-09 18:31; UTC

Rinkos pokalbiai

Some Fed Officials Supported Considering July Cut -- Market Talk

2025-07-09 17:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk -2-

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025-07-09 16:14; UTC

Įsigijimai, susijungimai, perėmimai

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025-07-09 16:12; UTC

Rinkos pokalbiai

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025-07-09 16:08; UTC

Rinkos pokalbiai

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025-07-09 15:31; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250M Private Placement

2025-07-09 15:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025-07-09 15:27; UTC

Rinkos pokalbiai

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025-07-09 14:36; UTC

Įsigijimai, susijungimai, perėmimai

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025-07-09 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025-07-09 14:26; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-09 14:26; UTC

Rinkos pokalbiai

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Akcijų palyginimas

Kainos pokytis

Xenon Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

76.1% į viršų

12 mėnesių prognozė

Vidutinis 55.33 USD  76.1%

Aukščiausias 65 USD

Žemiausias 47 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xenon Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

15

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

34.81 / 38.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Neutral Evidence

Rinkos nuotaikos

By Acuity

343 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.